APO Research
Talk to an analyst

APO RESEARCH · REPORT

Renin-Angiotensin-System (RAS)-Acting Agent

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Renin-Angiotensin-System (RAS)-Acting Agent Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

22 December 2025197 pages

Choose your research edition.

Industry ResearchRenin-Angiotensin-System (RAS)-Acting Agent Industry Research Report 2026127 pages · $2,950 USDIndustry Growth & TrendsGlobal Renin-Angiotensin-System (RAS)-Acting Agent Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Renin-Angiotensin-System (RAS)-Acting Agent Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Renin-Angiotensin-System (RAS)-Acting Agent Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Renin-Angiotensin-System (RAS)-Acting Agent Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Renin-Angiotensin-System (RAS)-Acting Agent market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Renin-Angiotensin-System (RAS)-Acting Agent is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Renin-Angiotensin-System (RAS)-Acting Agent is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Renin-Angiotensin-System (RAS)-Acting Agent is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Renin-Angiotensin-System (RAS)-Acting Agent is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Renin-Angiotensin-System (RAS)-Acting Agent include Takeda Pharmaceutical Company Limited, Sanofi S.A., Johnson & Johnson, Novartis AG, Merck & Co., Inc., Pfizer, Inc., Daiichi Sankyo Company,Limited, AstraZeneca plc and Bristol-Myers Squibb Company, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Renin-Angiotensin-System (RAS)-Acting Agent market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Renin-Angiotensin-System (RAS)-Acting Agent and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Renin-Angiotensin-System (RAS)-Acting Agent sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Renin-Angiotensin-System (RAS)-Acting Agent market size, projected growth trends, production technologies, key applications, and end-use industries.

Renin-Angiotensin-System (RAS)-Acting Agent Segment by Company

Takeda Pharmaceutical Company Limited

Sanofi S.A.

Johnson & Johnson

Novartis AG

Merck & Co., Inc.

Pfizer, Inc.

Daiichi Sankyo Company,Limited

AstraZeneca plc

Bristol-Myers Squibb Company

Boehringer lngelheim GmbH

Renin-Angiotensin-System (RAS)-Acting Agent Segment by Type

Angiotensin Converting Enzyme Inhibitors (ACEi)

Angiotensin Receptor Blockers (ARBs)

Renin-Angiotensin-System (RAS)-Acting Agent Segment by Application

Heart Failure

Chronic Kidney Disease

Hypertension

Other

Renin-Angiotensin-System (RAS)-Acting Agent Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Renin-Angiotensin-System (RAS)-Acting Agent market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Renin-Angiotensin-System (RAS)-Acting Agent and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Renin-Angiotensin-System (RAS)-Acting Agent.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Renin-Angiotensin-System (RAS)-Acting Agent market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Renin-Angiotensin-System (RAS)-Acting Agent manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Renin-Angiotensin-System (RAS)-Acting Agent in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Renin-Angiotensin-System (RAS)-Acting Agent in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Renin-Angiotensin-System (RAS)-Acting Agent Industry Trends Table 2. Renin-Angiotensin-System (RAS)-Acting Agent Industry Drivers Table 3. Renin-Angiotensin-System (RAS)-Acting Agent Industry Opportunities and Challenges Table 4. Renin-Angiotensin-System (RAS)-Acting Agent Industry Restraints Table 5. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales by Manufacturers (k units) & (2021-2026) Table 8. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Manufacturers Table 9. Global Renin-Angiotensin-System (RAS)-Acting Agent Average Sales Price (US$/unit) of Manufacturers (2021-2026) Table 10. Global Renin-Angiotensin-System (RAS)-Acting Agent Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Renin-Angiotensin-System (RAS)-Acting Agent Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Renin-Angiotensin-System (RAS)-Acting Agent Manufacturers, Product Type & Application Table 13. Global Renin-Angiotensin-System (RAS)-Acting Agent Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Renin-Angiotensin-System (RAS)-Acting Agent by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Angiotensin Converting Enzyme Inhibitors (ACEi) Table 17. Major Manufacturers of Angiotensin Receptor Blockers (ARBs) Table 18. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales by Type 2021 VS 2025 VS 2032 (k units) Table 19. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales by Type (2021-2026) & (k units) Table 20. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales by Type (2027-2032) & (k units) Table 21. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Type (2021-2026) Table 22. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Type (2027-2032) Table 23. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 24. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Type (2021-2026) & (k units) Table 25. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Type (2027-2032) & (k units) Table 26. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue Market Share by Type (2021-2026) Table 27. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Heart Failure Table 29. Major Manufacturers of Chronic Kidney Disease Table 30. Major Manufacturers of Hypertension Table 31. Major Manufacturers of Other Table 32. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales by Application 2021 VS 2025 VS 2032 (k units) Table 33. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales by Application (2021-2026) & (k units) Table 34. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales by Application (2027-2032) & (k units) Table 35. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Application (2021-2026) Table 36. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Application (2027-2032) Table 37. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 38. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Application (2021-2026) & (k units) Table 39. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Application (2027-2032) & (k units) Table 40. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue Market Share by Application (2021-2026) Table 41. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue Market Share by Application (2027-2032) Table 42. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 43. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales by Region (2021-2026) & (k units) Table 44. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Region (2021-2026) Table 45. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Forecasted by Region (2027-2032) & (k units) Table 46. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Forecasted Market Share by Region (2027-2032) Table 47. North America Renin-Angiotensin-System (RAS)-Acting Agent Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 48. North America Renin-Angiotensin-System (RAS)-Acting Agent Sales by Country (2021-2026) & (k units) Table 49. North America Renin-Angiotensin-System (RAS)-Acting Agent Sales by Country (2027-2032) & (k units) Table 50. Europe Renin-Angiotensin-System (RAS)-Acting Agent Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 51. Europe Renin-Angiotensin-System (RAS)-Acting Agent Sales by Country (2021-2026) & (k units) Table 52. Europe Renin-Angiotensin-System (RAS)-Acting Agent Sales by Country (2027-2032) & (k units) Table 53. Asia Pacific Renin-Angiotensin-System (RAS)-Acting Agent Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 54. Asia Pacific Renin-Angiotensin-System (RAS)-Acting Agent Sales by Country (2021-2026) & (k units) Table 55. Asia Pacific Renin-Angiotensin-System (RAS)-Acting Agent Sales by Country (2027-2032) & (k units) Table 56. South America, Middle East and Africa Renin-Angiotensin-System (RAS)-Acting Agent Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 57. South America, Middle East and Africa Renin-Angiotensin-System (RAS)-Acting Agent Sales by Country (2021-2026) & (k units) Table 58. South America, Middle East and Africa Renin-Angiotensin-System (RAS)-Acting Agent Sales by Country (2027-2032) & (k units) Table 59. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Region (2021-2026) & (US$ Million) Table 61. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Region (2027-2032) & (US$ Million) Table 62. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue Market Share by Region (2021-2026) Table 63. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue Market Share by Region (2027-2032) Table 64. Takeda Pharmaceutical Company Limited Company Information Table 65. Takeda Pharmaceutical Company Limited Business Overview Table 66. Takeda Pharmaceutical Company Limited Renin-Angiotensin-System (RAS)-Acting Agent Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Takeda Pharmaceutical Company Limited Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolio Table 68. Takeda Pharmaceutical Company Limited Recent Development Table 69. Sanofi S.A. Company Information Table 70. Sanofi S.A. Business Overview Table 71. Sanofi S.A. Renin-Angiotensin-System (RAS)-Acting Agent Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Sanofi S.A. Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolio Table 73. Sanofi S.A. Recent Development Table 74. Johnson & Johnson Company Information Table 75. Johnson & Johnson Business Overview Table 76. Johnson & Johnson Renin-Angiotensin-System (RAS)-Acting Agent Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Johnson & Johnson Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolio Table 78. Johnson & Johnson Recent Development Table 79. Novartis AG Company Information Table 80. Novartis AG Business Overview Table 81. Novartis AG Renin-Angiotensin-System (RAS)-Acting Agent Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Novartis AG Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolio Table 83. Novartis AG Recent Development Table 84. Merck & Co., Inc. Company Information Table 85. Merck & Co., Inc. Business Overview Table 86. Merck & Co., Inc. Renin-Angiotensin-System (RAS)-Acting Agent Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Merck & Co., Inc. Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolio Table 88. Merck & Co., Inc. Recent Development Table 89. Pfizer, Inc. Company Information Table 90. Pfizer, Inc. Business Overview Table 91. Pfizer, Inc. Renin-Angiotensin-System (RAS)-Acting Agent Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Pfizer, Inc. Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolio Table 93. Pfizer, Inc. Recent Development Table 94. Daiichi Sankyo Company,Limited Company Information Table 95. Daiichi Sankyo Company,Limited Business Overview Table 96. Daiichi Sankyo Company,Limited Renin-Angiotensin-System (RAS)-Acting Agent Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 97. Daiichi Sankyo Company,Limited Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolio Table 98. Daiichi Sankyo Company,Limited Recent Development Table 99. AstraZeneca plc Company Information Table 100. AstraZeneca plc Business Overview Table 101. AstraZeneca plc Renin-Angiotensin-System (RAS)-Acting Agent Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 102. AstraZeneca plc Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolio Table 103. AstraZeneca plc Recent Development Table 104. Bristol-Myers Squibb Company Company Information Table 105. Bristol-Myers Squibb Company Business Overview Table 106. Bristol-Myers Squibb Company Renin-Angiotensin-System (RAS)-Acting Agent Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 107. Bristol-Myers Squibb Company Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolio Table 108. Bristol-Myers Squibb Company Recent Development Table 109. Boehringer lngelheim GmbH Company Information Table 110. Boehringer lngelheim GmbH Business Overview Table 111. Boehringer lngelheim GmbH Renin-Angiotensin-System (RAS)-Acting Agent Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 112. Boehringer lngelheim GmbH Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolio Table 113. Boehringer lngelheim GmbH Recent Development Table 114. Key Raw Materials Table 115. Raw Materials Key Suppliers Table 116. Renin-Angiotensin-System (RAS)-Acting Agent Distributors List Table 117. Renin-Angiotensin-System (RAS)-Acting Agent Customers List Table 118. Research Programs/Design for This Report Table 119. Authors List of This Report Table 120. Secondary Sources Table 121. Primary Sources List of Figures Figure 1. Renin-Angiotensin-System (RAS)-Acting Agent Product Image Figure 2. Global Renin-Angiotensin-System (RAS)-Acting Agent Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Renin-Angiotensin-System (RAS)-Acting Agent Market Size (2021-2032) & (US$ Million) Figure 4. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales (2021-2032) & (k units) Figure 5. Global Renin-Angiotensin-System (RAS)-Acting Agent Average Price (US$/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Renin-Angiotensin-System (RAS)-Acting Agent Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Angiotensin Converting Enzyme Inhibitors (ACEi) Image Figure 9. Angiotensin Receptor Blockers (ARBs) Image Figure 10. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 11. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Type (2021-2032) Figure 13. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 14. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue Market Share by Type (2021-2032) Figure 16. Heart Failure Image Figure 17. Chronic Kidney Disease Image Figure 18. Hypertension Image Figure 19. Other Image Figure 20. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 21. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share 2021 VS 2025 VS 2032 Figure 22. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Application (2021-2032) Figure 23. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 24. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue Market Share 2021 VS 2025 VS 2032 Figure 25. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue Market Share by Application (2021-2032) Figure 26. North America Renin-Angiotensin-System (RAS)-Acting Agent Sales and Growth Rate (2021-2032) & (k units) Figure 27. North America Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Country (2021-2032) Figure 28. U.S. Renin-Angiotensin-System (RAS)-Acting Agent Sales and Growth Rate (2021-2032) & (k units) Figure 29. Canada Renin-Angiotensin-System (RAS)-Acting Agent Sales and Growth Rate (2021-2032) & (k units) Figure 30. Mexico Renin-Angiotensin-System (RAS)-Acting Agent Sales and Growth Rate (2021-2032) & (k units) Figure 31. Europe Renin-Angiotensin-System (RAS)-Acting Agent Sales and Growth Rate (2021-2032) & (k units) Figure 32. Europe Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Country (2021-2032) Figure 33. Germany Renin-Angiotensin-System (RAS)-Acting Agent Sales and Growth Rate (2021-2032) & (k units) Figure 34. France Renin-Angiotensin-System (RAS)-Acting Agent Sales and Growth Rate (2021-2032) & (k units) Figure 35. U.K. Renin-Angiotensin-System (RAS)-Acting Agent Sales and Growth Rate (2021-2032) & (k units) Figure 36. Italy Renin-Angiotensin-System (RAS)-Acting Agent Sales and Growth Rate (2021-2032) & (k units) Figure 37. Netherlands Renin-Angiotensin-System (RAS)-Acting Agent Sales and Growth Rate (2021-2032) & (k units) Figure 38. Asia Pacific Renin-Angiotensin-System (RAS)-Acting Agent Sales and Growth Rate (2021-2032) & (k units) Figure 39. Asia Pacific Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Country (2021-2032) Figure 40. China Renin-Angiotensin-System (RAS)-Acting Agent Sales and Growth Rate (2021-2032) & (k units) Figure 41. Japan Renin-Angiotensin-System (RAS)-Acting Agent Sales and Growth Rate (2021-2032) & (k units) Figure 42. South Korea Renin-Angiotensin-System (RAS)-Acting Agent Sales and Growth Rate (2021-2032) & (k units) Figure 43. Southeast Asia Renin-Angiotensin-System (RAS)-Acting Agent Sales and Growth Rate (2021-2032) & (k units) Figure 44. India Renin-Angiotensin-System (RAS)-Acting Agent Sales and Growth Rate (2021-2032) & (k units) Figure 45. Australia Renin-Angiotensin-System (RAS)-Acting Agent Sales and Growth Rate (2021-2032) & (k units) Figure 46. South America, Middle East and Africa Renin-Angiotensin-System (RAS)-Acting Agent Sales and Growth Rate (2021-2032) & (k units) Figure 47. South America, Middle East and Africa Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Country (2021-2032) Figure 48. Brazil Renin-Angiotensin-System (RAS)-Acting Agent Sales and Growth Rate (2021-2032) & (k units) Figure 49. South Africa Renin-Angiotensin-System (RAS)-Acting Agent Sales and Growth Rate (2021-2032) & (k units) Figure 50. Saudi Arabia Renin-Angiotensin-System (RAS)-Acting Agent Sales and Growth Rate (2021-2032) & (k units) Figure 51. Turkey Renin-Angiotensin-System (RAS)-Acting Agent Sales and Growth Rate (2021-2032) & (k units) Figure 52. Argentina Renin-Angiotensin-System (RAS)-Acting Agent Sales and Growth Rate (2021-2032) & (k units) Figure 53. UAE Renin-Angiotensin-System (RAS)-Acting Agent Sales and Growth Rate (2021-2032) & (k units) Figure 54. Egypt Renin-Angiotensin-System (RAS)-Acting Agent Sales and Growth Rate (2021-2032) & (k units) Figure 55. Chile Renin-Angiotensin-System (RAS)-Acting Agent Sales and Growth Rate (2021-2032) & (k units) Figure 56. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 57. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 58. North America Renin-Angiotensin-System (RAS)-Acting Agent Revenue (2021-2032) & (US$ Million) Figure 59. North America Renin-Angiotensin-System (RAS)-Acting Agent Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Europe Renin-Angiotensin-System (RAS)-Acting Agent Revenue (2021-2032) & (US$ Million) Figure 61. Europe Renin-Angiotensin-System (RAS)-Acting Agent Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Asia-Pacific Renin-Angiotensin-System (RAS)-Acting Agent Revenue (2021-2032) & (US$ Million) Figure 63. Asia-Pacific Renin-Angiotensin-System (RAS)-Acting Agent Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. South America, Middle East and Africa Renin-Angiotensin-System (RAS)-Acting Agent Revenue (2021-2032) & (US$ Million) Figure 65. South America, Middle East and Africa Renin-Angiotensin-System (RAS)-Acting Agent Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Renin-Angiotensin-System (RAS)-Acting Agent Value Chain Figure 67. Manufacturing Cost Structure Figure 68. Renin-Angiotensin-System (RAS)-Acting Agent Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Angiotensin Converting Enzyme Inhibitors (ACEi)
  • Angiotensin Receptor Blockers (ARBs)
Applications
  • Heart Failure
  • Chronic Kidney Disease
  • Hypertension
  • Other
Companies covered
  • Takeda Pharmaceutical Company Limited
  • Sanofi S.A.
  • Johnson & Johnson
  • Novartis AG
  • Merck & Co., Inc.
  • Pfizer, Inc.
  • Daiichi Sankyo Company,Limited
  • AstraZeneca plc
  • Bristol-Myers Squibb Company
  • Boehringer lngelheim GmbH

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Renin-Angiotensin-System (RAS)-Acting Agent Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Renin-Angiotensin-System (RAS)-Acting Agent Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Renin-Angiotensin-System (RAS)-Acting Agent Market Dynamics
  1. 2.1 Renin-Angiotensin-System (RAS)-Acting Agent Industry Trends
  2. 2.2 Renin-Angiotensin-System (RAS)-Acting Agent Industry Drivers
  3. 2.3 Renin-Angiotensin-System (RAS)-Acting Agent Industry Opportunities and Challenges
  4. 2.4 Renin-Angiotensin-System (RAS)-Acting Agent Industry Restraints
3 Renin-Angiotensin-System (RAS)-Acting Agent Market by Manufacturers
  1. 3.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales by Manufacturers (2021-2026)
  3. 3.3 Global Renin-Angiotensin-System (RAS)-Acting Agent Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Renin-Angiotensin-System (RAS)-Acting Agent Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Renin-Angiotensin-System (RAS)-Acting Agent Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Renin-Angiotensin-System (RAS)-Acting Agent Manufacturers, Product Type & Application
  7. 3.7 Global Renin-Angiotensin-System (RAS)-Acting Agent Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Renin-Angiotensin-System (RAS)-Acting Agent Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Renin-Angiotensin-System (RAS)-Acting Agent Tier 1, Tier 2, and Tier 3
4 Renin-Angiotensin-System (RAS)-Acting Agent Market by Type
  1. 4.1 Renin-Angiotensin-System (RAS)-Acting Agent Type Introduction
  2. 4.1.1 Angiotensin Converting Enzyme Inhibitors (ACEi)
  3. 4.1.2 Angiotensin Receptor Blockers (ARBs)
  4. 4.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales by Type
  5. 4.2.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales by Type (2021-2032)
  7. 4.2.3 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Type (2021-2032)
  8. 4.3 Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Type
  9. 4.3.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Type (2021-2032)
  11. 4.3.3 Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue Market Share by Type (2021-2032)
5 Renin-Angiotensin-System (RAS)-Acting Agent Market by Application
  1. 5.1 Renin-Angiotensin-System (RAS)-Acting Agent Application Introduction
  2. 5.1.1 Heart Failure
  3. 5.1.2 Chronic Kidney Disease
  4. 5.1.3 Hypertension
  5. 5.1.4 Other
  6. 5.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales by Application
  7. 5.2.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales by Application (2021-2032)
  9. 5.2.3 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Application (2021-2032)
  10. 5.3 Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Application
  11. 5.3.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Application (2021-2032)
  13. 5.3.3 Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue Market Share by Application (2021-2032)
6 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales by Region
  1. 6.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales by Region (2021-2032)
  3. 6.2.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales by Region (2021-2026)
  4. 6.2.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Renin-Angiotensin-System (RAS)-Acting Agent Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Renin-Angiotensin-System (RAS)-Acting Agent Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Renin-Angiotensin-System (RAS)-Acting Agent Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Renin-Angiotensin-System (RAS)-Acting Agent Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Renin-Angiotensin-System (RAS)-Acting Agent Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Renin-Angiotensin-System (RAS)-Acting Agent Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Renin-Angiotensin-System (RAS)-Acting Agent Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Renin-Angiotensin-System (RAS)-Acting Agent Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Region
  1. 7.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Region
  2. 7.1.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Region (2021-2026)
  4. 7.1.3 Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Region (2027-2032)
  5. 7.1.4 Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Renin-Angiotensin-System (RAS)-Acting Agent Revenue (2021-2032)
  8. 7.2.2 North America Renin-Angiotensin-System (RAS)-Acting Agent Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Renin-Angiotensin-System (RAS)-Acting Agent Revenue (2021-2032)
  11. 7.3.2 Europe Renin-Angiotensin-System (RAS)-Acting Agent Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Renin-Angiotensin-System (RAS)-Acting Agent Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Renin-Angiotensin-System (RAS)-Acting Agent Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Renin-Angiotensin-System (RAS)-Acting Agent Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Renin-Angiotensin-System (RAS)-Acting Agent Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda Pharmaceutical Company Limited
  2. 8.1.1 Takeda Pharmaceutical Company Limited Company Information
  3. 8.1.2 Takeda Pharmaceutical Company Limited Business Overview
  4. 8.1.3 Takeda Pharmaceutical Company Limited Renin-Angiotensin-System (RAS)-Acting Agent Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Pharmaceutical Company Limited Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolio
  6. 8.1.5 Takeda Pharmaceutical Company Limited Recent Developments
  7. 8.2 Sanofi S.A.
  8. 8.2.1 Sanofi S.A. Company Information
  9. 8.2.2 Sanofi S.A. Business Overview
  10. 8.2.3 Sanofi S.A. Renin-Angiotensin-System (RAS)-Acting Agent Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Sanofi S.A. Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolio
  12. 8.2.5 Sanofi S.A. Recent Developments
  13. 8.3 Johnson & Johnson
  14. 8.3.1 Johnson & Johnson Company Information
  15. 8.3.2 Johnson & Johnson Business Overview
  16. 8.3.3 Johnson & Johnson Renin-Angiotensin-System (RAS)-Acting Agent Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Johnson & Johnson Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolio
  18. 8.3.5 Johnson & Johnson Recent Developments
  19. 8.4 Novartis AG
  20. 8.4.1 Novartis AG Company Information
  21. 8.4.2 Novartis AG Business Overview
  22. 8.4.3 Novartis AG Renin-Angiotensin-System (RAS)-Acting Agent Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Novartis AG Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolio
  24. 8.4.5 Novartis AG Recent Developments
  25. 8.5 Merck & Co., Inc.
  26. 8.5.1 Merck & Co., Inc. Company Information
  27. 8.5.2 Merck & Co., Inc. Business Overview
  28. 8.5.3 Merck & Co., Inc. Renin-Angiotensin-System (RAS)-Acting Agent Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Merck & Co., Inc. Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolio
  30. 8.5.5 Merck & Co., Inc. Recent Developments
  31. 8.6 Pfizer, Inc.
  32. 8.6.1 Pfizer, Inc. Company Information
  33. 8.6.2 Pfizer, Inc. Business Overview
  34. 8.6.3 Pfizer, Inc. Renin-Angiotensin-System (RAS)-Acting Agent Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Pfizer, Inc. Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolio
  36. 8.6.5 Pfizer, Inc. Recent Developments
  37. 8.7 Daiichi Sankyo Company,Limited
  38. 8.7.1 Daiichi Sankyo Company,Limited Company Information
  39. 8.7.2 Daiichi Sankyo Company,Limited Business Overview
  40. 8.7.3 Daiichi Sankyo Company,Limited Renin-Angiotensin-System (RAS)-Acting Agent Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Daiichi Sankyo Company,Limited Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolio
  42. 8.7.5 Daiichi Sankyo Company,Limited Recent Developments
  43. 8.8 AstraZeneca plc
  44. 8.8.1 AstraZeneca plc Company Information
  45. 8.8.2 AstraZeneca plc Business Overview
  46. 8.8.3 AstraZeneca plc Renin-Angiotensin-System (RAS)-Acting Agent Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 AstraZeneca plc Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolio
  48. 8.8.5 AstraZeneca plc Recent Developments
  49. 8.9 Bristol-Myers Squibb Company
  50. 8.9.1 Bristol-Myers Squibb Company Company Information
  51. 8.9.2 Bristol-Myers Squibb Company Business Overview
  52. 8.9.3 Bristol-Myers Squibb Company Renin-Angiotensin-System (RAS)-Acting Agent Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Bristol-Myers Squibb Company Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolio
  54. 8.9.5 Bristol-Myers Squibb Company Recent Developments
  55. 8.10 Boehringer lngelheim GmbH
  56. 8.10.1 Boehringer lngelheim GmbH Company Information
  57. 8.10.2 Boehringer lngelheim GmbH Business Overview
  58. 8.10.3 Boehringer lngelheim GmbH Renin-Angiotensin-System (RAS)-Acting Agent Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Boehringer lngelheim GmbH Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolio
  60. 8.10.5 Boehringer lngelheim GmbH Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Renin-Angiotensin-System (RAS)-Acting Agent Value Chain Analysis
  2. 9.1.1 Renin-Angiotensin-System (RAS)-Acting Agent Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Renin-Angiotensin-System (RAS)-Acting Agent Production Mode & Process
  6. 9.2 Renin-Angiotensin-System (RAS)-Acting Agent Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Renin-Angiotensin-System (RAS)-Acting Agent Distributors
  9. 9.2.3 Renin-Angiotensin-System (RAS)-Acting Agent Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst